Pacira Pharm Inc (PCRX)

$22.36 +0.30 (1.36%)
Market Cap 1.02B
Revenue (ttm) 674.98M
Net Income (ttm) 41.96M
EPS (ttm) N/A
PE Ratio 9.51
Forward PE 9.85
Profit Margin 6.22%
Debt to Equity Ratio 0.41
Volume 930,300
Avg Vol 768,672
Day's Range N/A - N/A
Shares Out 46.17M
Stochastic %K 93%
Beta 0.76
Analysts Sell
Price Target $21.50

Latest News on PCRX

The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Pacira BioSciences, Inc.

Jan 17, 2025, 10:30 AM EST - 17 hours ago

The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Pacira BioSciences, Inc.

Pacira BioSciences, Inc. Is Being Sued For Securities Law Violations And Impacted Shareholders Are Urged To Contact The Schall Law Firm

Jan 16, 2025, 10:45 AM EST - 1 day ago

Pacira BioSciences, Inc. Is Being Sued For Securities Law Violations And Impacted Shareholders Are Urged To Contact The Schall Law Firm

Pacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights - PCRX

Jan 16, 2025, 5:45 AM EST - 1 day ago

Pacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights - PCRX

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

Jan 15, 2025, 11:22 AM EST - 2 days ago

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Pacira BioSciences Inc

Jan 15, 2025, 11:15 AM EST - 2 days ago

The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Pacira BioSciences Inc

Pacira BioSciences, Inc. Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm

Jan 14, 2025, 8:00 PM EST - 3 days ago

Pacira BioSciences, Inc. Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm

Rosen Law Firm Urges Pacira BioSciences, Inc. (NASDAQ: PCRX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Jan 13, 2025, 9:19 PM EST - 4 days ago

Rosen Law Firm Urges Pacira BioSciences, Inc. (NASDAQ: PCRX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 4:01 PM EST - 15 days ago

Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.

Dec 11, 2024, 8:05 AM EST - 5 weeks ago

DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Dec 6, 2024, 8:00 AM EST - 6 weeks ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Pacira Awarded New U.S. Patent Covering EXPAREL Composition

Dec 3, 2024, 7:30 AM EST - 6 weeks ago

Pacira Awarded New U.S. Patent Covering EXPAREL Composition

Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses

Nov 25, 2024, 1:25 PM EST - 7 weeks ago

Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

Nov 14, 2024, 10:05 AM EST - 2 months ago

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:09 PM EST - 2 months ago

Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript

Pacira BioSciences Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:00 PM EST - 2 months ago

Pacira BioSciences Reports Third Quarter 2024 Financial Results

Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024

Oct 30, 2024, 8:00 AM EDT - 2 months ago

Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

Oct 21, 2024, 8:00 AM EDT - 3 months ago

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

Oct 3, 2024, 8:00 AM EDT - 3 months ago

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

Sep 26, 2024, 8:00 AM EDT - 4 months ago

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders

Sep 25, 2024, 8:15 AM EDT - 4 months ago

DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders

Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path

Aug 12, 2024, 2:19 PM EDT - 5 months ago

Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path